Testing MR-guided radiation therapy for several types of cancer
Tests whether MR-guided radiation can be given safely to adults with cancer.
Plain-language title generated from the registry record
Registry title: Stereotactic Magnetic Resonance Guided Radiation Therapy
Key facts
- Where
- Boston, United StatesSee the 2 sites
Where in United States
- Brigham & Women's HospitalBoston, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dana-Farber Cancer Institute
- Trial code
- NCT04115254
- Record updated
- 13 November 2025
- Original description
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.Read full original descriptionShow less
A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
* The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures
Inclusion: Participants must have a confirmed malignancy requiring stereotactic body radiation therapy. See specific disease site cohorts for more details; Tumor size ≤ 7cm; Age 18 years of older; ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A); Ability to understand and the willingness to sign a written informed consent document; Specific eligibility requirements for each disease site with be covered in each specific cohort.
Exclusion: Specific exclusion requirements for each disease site with be covered in each specific cohort; History of allergic reactions attributed to gadolinium-based IV contrast; -- Note: If a patient will not receive contrast, this is not applicable; Pregnant women are excluded from this study; Severe claustrophobia or anxiety; Participants who cannot undergo an MRI.